Vivoryon Therapeutics N.V.
VVY.AS · AMS
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | -€0 |
| % Growth | – | – | 100% | – |
| Gross Profit | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | – | – | 114.5% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | – | – | 483.5% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | – | – | 486.9% |
| EPS Diluted | -0.21 | -0.27 | -0.52 | -0.72 |
| % Growth | 22.2% | 48.1% | 27.8% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | -€0 | -€0 | €0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |